glp-1 layoffs news Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Novo Nordisk CEO warns of

4,5 Clinical outcomes Across phase II data for the once-daily, non-peptide GLP-1R agonist orforglipron in obese adults without diabetes, mean weight loss of 9.414.7% 6 was reported by week 36, depending on the dose, as compared to 2.3% with placebo

Lyle, A

It also normalizes hormonal stress responses in humans with high-trait anxiety

To ensure maximum stability and penetration, it is housed in specialized phospholipid capsules

03 Wrong BAC water volume Recalculate concentration with the actual volume added

In my 30s my skin is beginning to show early signs of aging, and this feels like the right signal to help it look youthful again